Intracameral Antibiotic Safety Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02590523|
Recruitment Status : Not yet recruiting
First Posted : October 29, 2015
Last Update Posted : March 20, 2019
|Condition or disease||Intervention/treatment||Phase|
|Intracameral Antibiotics Cataract Surgery Phacoemulsification Endophthalmitis Vancomycin Moxifloxacin||Drug: Vancomycin Drug: Moxifloxacin Drug: Placebo||Phase 3|
Use of injectable prophylactic intracameral antibiotics during cataract surgery is gaining popularity worldwide due to the growing body of scientific evidence supporting its use. To date, there is no sterile-packaged antibiotic that has FDA approval for this indication. Surgeons using intracameral injectable antibiotics during cataract surgery must use existing pharmaceuticals off-label and/or rely on imprecise and sub-sterile compounding pharmacies to dispense these types of medications. Both of these scenarios may pose significant risk to patient safety.
Description of the Treatment: Approximately 0.2 mL of either pre-loaded sterile vancomycin hydrochloride 1% solution (1 mg/0.1 mL of normal saline) or moxifloxacin hydrochloride 0.15% solution (150 μg/0.1 mL of normal saline) is injected into the eye with a blunt tip 30 gauge cannula through a small clear corneal incision as the last step in the cataract removal procedure. The purpose of the treatment is for prophylaxis against post-operative infections and endophthalmitis.
Description of Effector Pharmaceuticals/Drugs: Vancomycin is a hydrophilic glycopeptide antibiotic that has been well studied in many different forms: intravenous injectable, oral tablet and even topical eye drop solutions. It is derived from Actinobacteria spp. Moxifloxacin is a synthetic fourth generation fluoroquinolone and has, likewise, been available in many forms including intravenous injectable, oral tablet and topical eye drop solutions. In this study, a contracted compounding pharmacy will produce the two pharmaceutical agents at the concentration/dosage mentioned above under the USP 797 guidelines.
Therapeutic Mode of Action: The primary mode of action for vancomycin is inhibition of cell wall synthesis in gram positive bacteria. The molecule forms hydrogen bonds with terminal amnio acid moieties of the N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) polymer. The disruption to the polymerization and cross-linking of NAM-NAG complexes undermines the structural integrity of the bacterial organism leading to bacteriostasis and eventually cell death. The primary mode of action for moxifloxacin is inhibiting DNA gyrases, both type II topoisomerase and topoisomerase IV. These enzymes are essential for bacterial DNA replication to occur.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Intracameral Antibiotic Safety Study|
|Estimated Study Start Date :||January 2020|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||January 2021|
Experimental: A: Vancomycin
Intracameral vancomycin injection given at conclusion of cataract case
Intracameral vancomycin injection during cataract surgery
Experimental: B: Moxifloxacin
Intracameral moxifloxacin injection given at conclusion of cataract case
Intracameral moxifloxacin injection during cataract surgery
Placebo Comparator: C: Placebo
Intracameral placebo injection with BSS given at conclusion of cataract case
Intracameral placebo injection with BSS during cataract surgery
- Occurrence of adverse event [ Time Frame: 3 months ]
- Postoperative visual acuity measured by best spectacle corrected [ Time Frame: 3 months ]best spectacle corrected
- Endothelial cell count measured by specular microscopy [ Time Frame: 3 months ]specular microscopy
- Rate of postoperative complication [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02590523
|Contact: Sloan Rush, MDfirstname.lastname@example.org|
|Contact: Sunday Fowleremail@example.com|